Search Results
21 protocol(s) meet the specified criteria
100305Open  
Phase I, Open-Label, Multicenter, Dose-Escalation Study of mRNA-2416, a Lipid Nanoparticle Encapsulated mRNA Encoding Human Ox40l, for Intratumoral Injection to Patients with Advanced Malignancies

100308Open  
Phase I/IB, Open-Label, Multicenter, Dose-Escalation Study of NIS793 in Combination with PDR001 in Adult Patients with Advanced Malignancies

100700Open  
Phase III, Randomized Study of Adjuvant Immunotherapy with Nivolumab Combined with Ipilimumab versus Ipilimumab or Nivolumab Monotherapy after Complete Resection of Stage IIIB/C/D or Stage IV Melanoma

100701Open  
Open-Label, Multicenter Phase IIA Study to Evaluate the Efficacy, Safety, and Immunological Response of OBP-301, Telomerase Specific Replication-Competent Oncolytic Adenovirus in Patients with Unresectable Metastatic Melanoma

101981Open  
Phase I/II Study to Assess the Safety and Efficacy of Intratumoral IMO-2125 in Combination with Ipilimumab or Pembrolizumab in Patients with Metastatic Melanoma

102346Open  
Phase II Neoadjuvant Trial of Nivolumab in Combination with HF10 Oncolytic Viral Therapy in Resectable Stage IIIB, IIIC, IVM1A Melanoma (Neo-NivoHF10)

103138Open  
Multicenter Phase II, Adaptive, Open-Label Trial of Intratumoral pIL-12 plus Electroporation in Combination with Pembrolizumab in Patients with Stage III/IV Melanoma who are Progressing on either Pembrolizumab or Nivolumab Treatment

43948Open  
Multi-Tracer PET Assessment of Response in Various Malignancies in Investigational and Recently Approved Therapeutic Agents

76066Open  
Phase IB/II, Multicenter, Trial of Talimogene Laherparepvec in Combination with Pembrolizumab (MK-3475) for Treatment of Unresectable, Stage IIIB to IVM1c Melanoma (MASTERKEY-265)

76853Open  
Phase I/IB Study of MGCD516 in Patients with Advanced Solid Tumor Malignancies

77641Open  
Registry Study to Evaluate the Survival and Long-Term Safety of Subjects with Melanoma Who Previously Received Talimogene Laherparepvec

78383Open  
Randomized, Phase II Trial of Intermittent versus Continuous Dosing of Dabrafenib and Trametinib in BRAFV600E/K Mutant Melanoma

80350Open  
Prospective, Randomized, Blinded, Placebo-Controlled, Phase IIb Trial of an Autologous Tumor Lysate (TL) plus Yeast Cell Wall Particles (YCWP) plus Dendritic Cells (DC) Vaccine versus Unloaded YCWP plus DC in Stage III and Stage IV (Resected) Melanoma to Prevent Recurrence

81139Open  
PV-10 versus Systemic Chemotherapy or Intralesional Oncolytic Viral Therapy for Treatment of Locally Advanced Cutaneous Melanoma without Distant Metastases

81405Open  
Phase I/IIA Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of PLX8394 in Patients with Advanced, Unresectable Solid Tumors

82831Open  
Phase I/II, Open-Label, Multicenter Study of the Safety and Efficacy of LAG525 Single Agent and in Combination with PDR001 Administered to Patients with Advanced Malignancies

88893Open  
Phase IB Study of Intratumoral CAVATAK (Coxsackievirus A21) and Ipilimumab in Patients with Advanced Melanoma

89466Open  
Phase IB, Open-Label, Multicenter, Dose-Escalation Trial of Intratumoral Injections of SD-101 in Combination with Pembrolizumab in Patients with Metastatic Melanoma

90996Open  
Phase II Study of REGN2810, A Fully Human Monoclonal Antibody to Programmed Death - 1 (Pd-1), in Patients with Advanced Cutaneous Squamous Cell Carcinoma

91557Open  
Phase IB Trial of Neoadjuvant X4P-001 Alone and with Pembrolizumab in Patients with Resectable Melanoma

97426Open  
Phase II and Pilot Trial of PD-1 Blockade with MK-3475 (Pembrolizumab) in Patients with Resectable or Unsectable Desmoplastic Melanoma (DM)